Circulating tumor cells (CTCs), described by catch from blood vessels with anti-EpCAM antibodies, established prognostic benefit in specific epithelial cancers, but less is well known about their utility for evaluating patient response to molecularly targeted agents via measurement of pharmacodynamic (PD) endpoints. carcinomas suggests extreme caution in the usage of cell-surface differentiation marker-based options for… Continue reading Circulating tumor cells (CTCs), described by catch from blood vessels with